Clinical Trials Logo

Clinical Trial Summary

Infections with enterobacteria producing carbapenemases at the University Hospitals of Strasbourg - descriptive epidemiology and risk factors for infection in the event of colonization There is a worrying situation of an increase in the number of patients colonized with carbapenemase-producing Enterobacteriaceae (CPE) at HUS. 7 to 15% of patients colonized with EPC would develop an infection with EPC. The cohorts published mainly concern patients hospitalized in intensive care. The associated mortality reported in the literature is high (> 25%) and greater than that associated with infection with the same bacterium sensitive to carbapenems.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04995965
Study type Observational
Source University Hospital, Strasbourg, France
Contact Yves HANSMANN, MD, PhD
Phone 33 3 69 55 09 78
Email yves.hansmann@chru-strasbourg.fr
Status Recruiting
Phase
Start date August 6, 2021
Completion date January 6, 2022